Waypoint Bio develops AI-driven design tools paired with an in‑house spatial pooled in vivo screening platform to create and validate CAR‑T and in vivo delivery vector designs aimed at solid tumors. The company combines computational exploration of complex design spaces with in vivo validation to learn which designs translate into meaningful effects on the tumor microenvironment. Waypoint plans to enter the clinic later this year with its first program and is using the new capital to run three CAR‑T trials in China. It is building out its platform to support additional in vivo CAR‑T targets and modalities. The company has attracted both new strategic investors and returning backers, indicating continued investor confidence as it advances clinical development.

Total raised

$39M

Funding rounds

3

Latest round

Series A

Latest activity

May 2026